Physician profile
Eric Michael Smith
NPI 1942767470
$2,887.38
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $952 · 2022: $798 · 2023: $899 · 2024: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.27 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $374.05 | 2021-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $199.46 | 2021-2023 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $164.01 | 2021-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.89 | 2021-2023 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $132.11 | 2022-2023 | |
| Astellas Pharma US INC | $131.55 | 2021-2024 | Veozah |
| Pfizer INC. | $129.57 | 2021-2024 | |
| Amgen INC. | $99.89 | 2021-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $98.92 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $87.08 | 2021-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $78.69 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $74.10 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.11 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $62.10 | 2023 | Austedo, Austedo Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $51.65 | 2021-2024 | Aptima |
| Djo, LLC | $41.25 | 2024 | Cmf |
| Biohaven Pharmaceuticals, INC. | $38.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $35.76 | 2023 | Rexulti, Nuedexta |
| Phadia US INC. | $32.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $30.51 | 2021 | |
| Seqirus USA INC | $30.02 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Exact Sciences Corporation | $24.82 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $23.44 | 2021 | |
| Sanofi Pasteur INC. | $21.20 | 2023 | |
| Philips North America LLC | $18.67 | 2021 | |
| Currax Pharmaceuticals LLC | $16.96 | 2023 | Onzetra Xsail, Contrave |
| Bardy Diagnostics, INC. | $15.10 | 2021 | |
| Glaxosmithkline, LLC. | $13.43 | 2021 | |
| Mylan Specialty L.P. | $13.34 | 2021 | |
| Daiichi Sankyo INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.